Fused Cyclic CRBN Modulator for Wee1 Protein Degradation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is an urgent need to develop novel CRBN modulators to target new substrate proteins for the treatment of various diseases, as existing immunomodulatory drugs like thalidomide, lenalidomide, and pomalidomide primarily target IKZF1/3 and CK1alpha, limiting their therapeutic potential.
Innovation Solution
A compound represented by formula (II) or its pharmaceutically acceptable salt is synthesized and identified through a process involving compound libraries, phenotypic screening, and mass spectrometry to promote Wee1 kinase ubiquitination and proteasome-mediated degradation, leveraging the CRBN ubiquitin ligase system for targeted protein degradation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If existing immunomodulatory drugs (thalidomide, lenalidomide, pomalidomide) are used to target CRBN, then degradation of IKZF1/3 and CK1alpha is achieved, but therapeutic potential is limited due to targeting only specific substrate proteins
Solution Approach 1:
The patent develops novel CRBN modulators that can target multiple different substrate proteins beyond IKZF1/3 and CK1alpha. The compound of formula (II) is designed to bind to CRBN and recruit various substrate proteins for degradation, enabling one drug to serve multiple therapeutic functions across different diseases by degrading different target proteins.
2Adaptability or versatility
If novel CRBN modulators are developed to target new substrate proteins, then therapeutic versatility is improved, but drug discovery complexity and screening requirements increase
Solution Approach 1:
The patent employs a pre-designed compound library with formula (II) that incorporates specific structural features (E, R1, T1, R2, R3 substituents) known to facilitate CRBN binding and substrate recruitment. This preliminary structuring of the library based on prior knowledge reduces the need for extensive de novo screening and accelerates the discovery of novel substrate-specific modulators.
Solution Approach 2:
The patent uses an intermediary screening approach where compound WX106 serves as a lead structure to identify and characterize new substrate proteins. Mass spectrometry and proteomics techniques act as intermediaries to detect which proteins are recruited and degraded by the compound, facilitating the identification of new therapeutic targets without requiring exhaustive testing of all possible substrates.
3Quantity of substance
If compound libraries are screened to identify CRBN-dependent cytotoxic compounds, then novel substrate targets are discovered, but screening time and resource requirements increase
Solution Approach 1:
The patent extracts and isolates the key functional elements required for CRBN modulation by focusing the compound library design on formula (II) structures that specifically engage CRBN. By extracting the essential pharmacophore features and building libraries around these validated structures, the screening process becomes more efficient and requires fewer compounds to identify novel substrate-specific modulators.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compound effectively down-regulates Wee1 protein levels in cancer cells, inducing mitotic catastrophe and enhancing sensitivity to DNA-damaging agents, demonstrating potential therapeutic efficacy against a range of diseases.
Implementation Method 1
The compound effectively down-regulates Wee1 protein levels in cancer cells by promoting Wee1 kinase ubiquitination and proteasome-mediated degradation
Implementation Method 2
The compound effectively down-regulates Wee1 protein levels in cancer cells by promoting Wee1 kinase ubiquitination and proteasome-mediated degradation
Data Source
AI summary
The present disclosure discloses a compound shown in formula (II) and a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising the compound as an active ingredient, and use thereof in the preparation of medicaments for protein degradation.